Tal Zaks Biography and Net Worth

Director of Teva Pharmaceutical Industries

Dr. Zaks, M.D., Ph.D., is a partner at OrbiMed Advisors LLC since November 2021.

From 2015 to 2021, he served as Chief Medical Officer of Moderna, Inc. From 2010 to 2015, he held senior development positions at Sanofi, including Senior Vice President and Head of Global Oncology. From 2008 to 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. From 2004 to 2008, he served as Director, Clinical Development and Translational Medicine at GlaxoSmithKline. From 1996-1999, he was a Postdoctoral Fellow at the National Cancer Institute.

Dr. Zaks has also served as an adjunct Associate Professor of Medicine at the University of Pennsylvania since 2004 and as an adjunct Associate Professor of Medicine at Tufts Medical Center since 2017. From 2016 to 2023, Dr. Zaks served on the Board of Directors of Adaptimmune Therapeutics plc.

Dr. Zaks received his M.D. and Ph.D. from Ben Gurion University, Israel, conducted post-doctoral research at the U.S. National Institutes of Health and completed clinical training in internal medicine at Temple University Hospital, followed by a fellowship in medical oncology at the University of Pennsylvania. He has also been awarded Ph.D. honoris causa from Bar-Ilan University, Israel.

Dr. Zaks serves as a Member of our Finance and Investment and Science and Technology Committees.

What is Tal Zvi Zaks' net worth?: The estimated net worth of Tal Zvi Zaks is at least $2.59 million as of August 5th, 2026. Zaks owns 73,247 shares of Teva Pharmaceutical Industries stock worth more than $2,594,921 as of August 10th. This net worth estimate does not reflect any other assets that Zaks may own. Learn More about Tal Zvi Zaks' net worth.
How do I contact Tal Zvi Zaks?: The corporate mailing address for Zaks and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Tal Zvi Zaks' contact information.
Has Tal Zvi Zaks been buying or selling shares of Teva Pharmaceutical Industries?: Within the last three months, Tal Zvi Zaks has sold $592.79 in Teva Pharmaceutical Industries stock. Most recently, Tal Zvi Zaks sold 17 shares of the business's stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $34.87, for a transaction totalling $592.79. Following the completion of the sale, the director now directly owns 73,247 shares of the company's stock, valued at $2,554,122.89. Learn More on Tal Zvi Zaks' trading history.
Who are Teva Pharmaceutical Industries' active insiders?: Teva Pharmaceutical Industries' insider roster includes Vikki Conway (Acting Head of Global Human Resources), Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Christine Fox (EVP, U.S. Commercial), Richard Francis (President, CEO & Director), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Placid Jover (Insider), Eliyahu Kalif (CFO), Roberto Mignone (Director), Mark Sabag (Insider), Brian Savage (Insider), Eli Shani (EVP), Matthew Shields (EVP), David Stark (VP), Amir Weiss (CAO), and Tal Zaks (Director). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?: During the last twelve months, insiders at the sold shares 21 times. They sold a total of 2,008,909 shares worth more than $63,467,336.24. The most recent insider tranaction occured on August, 5th when Director Tal Zvi Zaks sold 17 shares worth more than $592.79. Insiders at Teva Pharmaceutical Industries own 0.5% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.
Information on this page was last updated on 8/5/2026.

Tal Zvi Zaks Insider Trading History at Teva Pharmaceutical Industries

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/5/2026	Sell	17	$34.87	$592.79	73,247

Tal Zvi Zaks Buying and Selling Activity at Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Today's Range

Now: $35.81

$35.00

$35.92

50 Day Range

MA: $33.25

$30.19

$35.45

2 Week Range

Now: $35.81

$16.26

$37.35

Volume

3,022,714 shs

Average Volume

7,196,246 shs

Market Capitalization

$41.73 billion

P/E Ratio

59.56

Dividend Yield

N/A

Beta

0.86